Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.50 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.44 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12471398 | 0.91 | HRH3 (0.57) | HRH3TRPV6MEN1KMT2AALDH1A1 | |
| SCHEMBL12471396 | 0.91 | HRH3 (0.57) | HRH3TRPV6MEN1KMT2AALDH1A1 | |
| SCHEMBL29700588 | 0.85 | HRH3 (0.67) | HRH3MEN1KMT2A | |
| SCHEMBL12471111 | 0.82 | HRH3 (0.56) | HRH3 | |
| SCHEMBL12471106 | 0.82 | HRH3 (0.56) | HRH3 | |
| SCHEMBL1161522 | 0.81 | HPGDS (0.48) | HRH3HPGDSALDH1A1KDM4E | |
| SCHEMBL1161523 | 0.81 | HPGDS (0.48) | HRH3HPGDSALDH1A1KDM4E | |
| SCHEMBL11942474 | 0.80 | ENPP2 (0.52) | ALDH1A1 | |
| SCHEMBL1161617 | 0.80 | ENPP2 (0.52) | ALDH1A1 | |
| SCHEMBL1161619 | 0.80 | ENPP2 (0.52) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802659-B2 | Bicyclic aryl sphingosine 1-phosphate analogs | BIOGEN IDEC MA INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-8802659-B2 | Bicyclic aryl sphingosine 1-phosphate analogs | BIOGEN IDEC MA INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-20120190649-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN IDEC MA INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120190649-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN IDEC MA INC. (US) | 2012-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190649-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | S1PR1, S1PR3, S1PR4 | HRH3 613/4885PDK2 1662/4885HPGDS 1263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.